Long term outcome after transjugular intrahepatic portosystemic stent- shunt in non-transplant cirrhotics with hepatorenal syndrome: A phase II study

Gut

Volumn 47, Issue 2, 2000, Pages 288-295

  Brensing, K A ^a   Schild, H ^a   Sauerbruch, T ^a   Textor, J ^a   Perz, J ^a   Schiedermaier, P ^a   Raab, P ^a   Strunk, H ^a   Klehr, H U ^a   Kramer, H J ^a   Spengler, U ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Ascites; Hepatorenal syndrome; Liver cirrhosis; Portal hypertension; Renal failure; Transjugular intrahepatic portosystemic stent shunt

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; FEMALE; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FAILURE; MALE; PHASE 2 CLINICAL TRIAL; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SODIUM EXCRETION; SURVIVAL TIME;

FEASIBILITY STUDIES; FEMALE; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0033931614     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.2.288     Document Type: Article

References (48)

1. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993;105:229-36.
2. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
3. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome - experience in 300 patients. Transplantation 1991;51:428-30.
4. Keller F, Heinze H, Jochimsen F, Paßfall J, Schuppan D, Büttner P. Risk factors and outcome of 107 patients with decompensated liver disease and acute renal failure (including 26 patients with hepatorenal syndrome): The role of hemodialysis. Ren Fail 1995;17:135-46.
5. Ochs A, Rössle M, Haag K, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995;332:1192-7.
6. Lebrec D, Giuily N, Hadengue A, et al. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. J Hepatol 1996;25:135-44.
7. Lake JR, Ring E, LaBerge JM, Gordon R, Roberts J, Ascher N. Transjugular intrahepatic portacaval stent shunts in patients with renal insufficiency. Transplant Proc 1993;25:1766-7.
8. Ochs A, Rössle M, Haag K, et al. TIPS for hepatorenal syndrome. Hepatology 1994;20(Pt 2):114A.
9. Spahr L, Fenyves D, N'Guyen VV, et al. Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 1995;90:1169-71.
10. Lerut J, Goffette P, Laterre PF, Donataccio M, Reynaert MS, Otte JB. Sequential treatment of hepatorenal syndrome and posthepatic cirrhosis by intrahepatic portosystemic shunt (TIPSS) and liver transplantation. Hepatogastroenterology 1995;42:985-7.
11. Sturgis TM. Hepatorenal syndrome: resolution after transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol 1995;20:241-3.
12. Alam I, Bass NM, LaBerge JM, Ring E, Somberg KA. Treatment of hepatorenal syndrome with the transjugular intrahepatic shunt (TIPS). Gastroenterology 1995;108:A1024.
13. Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T. Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome. Lancet 1997;349:697-8.
14. Guevara M, Gines P, Bandi JC, et al. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. Hepatology 1998;28:416-22.
15. Rössle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994;330:165-71.
16. Conn HO. Transjugular intrahepatic portal-systemic shunts: The state of the art. Hepatology 1993;17:148-58.
17. Stanley AJ, Jalan R, Forrest EH, Hayes PC. Longterm follow up of transjugular intrahepatic portosystemic stent shunt (TIPSS) for the treatment of portal hypertension: results in 130 patients. Gut 1996;39:479-85.
18. Brensing KA, Neubrand M, Textor J, et al. Endoscopic manometry of esophageal varices: evaluation of a balloon technique compared with direct portal pressure measurement. J Hepatol 1998;29:94-102.
19. Fevery J, Van Cutsem E, Nevens F, Van Steenbergen W, Verbeckmoes R, DeGroote J. Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostaglandin E1 analogue) and albumin administration. J Hepatol 1990;11:153-8.
20. Lenz K, Hörtnagel H, Druml W, et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor. Gastroenterology 1991;101:1060-7.
21. Salo J, Gines A, Quer JC, et al. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. J Hepatol 1996;25:916-23.
22. Cervoni JP, Lecomte T, Cellier C, et al. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis. Am J Gastroenterol 1997;92:2113-14.
23. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998;27:35-41.
24. Kaffy F, Borderie C, Chagneau C, et al. Octreotide in the treatment of hepatorenal syndrome in cirrhotic patients. J Hepatol 1999;30:174.
25. Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-5.
26. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
27. Wong F, Blendis L. Therapy for hepatorenal syndrome. Gastroenterology 1998;115:503-4.
28. LeMoine O. Hepatorenal syndrome - outcome after liver transplantation. Nephrol Dial Transplant 1998;13:20-2.
29. Castells A, Salo J, Planas R, et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994;20:584-91.
30. Epstein M. Hepatorenal syndrome. In: Epstein M, ed. The kidney in liver disease, 4th edn. Philadelphia: Hanley and Belfus, 1996:75-108.
31. Brensing KA, Woitas R, Heller J, et al. Significantly impaired glomerular perfusion and filtration rate already in patients with compensated liver cirrhosis. Gastroenterology 1996;110:A1158.
32. Henriksen JH. Cirrhosis: Ascites and hepatorenal syndrome. Recent advances in pathogenesis. J Hepatol 1995;23(suppl 1):25-30.
33. Bataller R, Gines P, Guevara M, Arroyo V. Hepatorenal syndrome. Semin Liver Dis 1997;17:233-47.
34. Koppel MH, Cohburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome: evidence for the functional nature of renal failure in advanced liver disease. N Engl J Med 1969;280:1367-71.
35. Epstein M. The hepatorenal syndrome - newer perspectives. N Engl J Med 1992;327:1810-11.
36. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma endothelin immunoreactivity in liver disease and hepatorenal syndrome. N Engl J Med 1992;327:1774-8.
37. Henriksen JH, Ring-Larsen H. Hepatorenal disorders: role of sympathetic nervous system. Semin Liver Dis 1994;14:35-43.
38. Sacerdoti D, Balazy M, Angeli P, Gatta A, McGiff JC. Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest 1997;100:1264-70.
39. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium homeostasis in cirrhosis and refractory scites. Ann Intern Med 1995;122:816-22.
40. Quiroga J, Sangro B, Nunez M, et al. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995;21:986-94.
41. Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM. Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function. Hepatology 1995;21:709-16.
42. Martinet JP, Legault L, Cernacek P, et al. Changes in plasma endothelin-1 and big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites. J Hepatol 1996;25:700-6.
43. Gerbes AL, Gulberg V, Waggershauser T, Holl J, Reiser M. Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: Comparison of patients with ascites, with refractory ascites, or without ascites. Hepatology 1998;28:683-8.
44. Gerbes AL, Moller S, Gulberg V, Henriksen JH. Endothelin-1 and -3 plasma concentration in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-9.
45. Epstein M, Goligorsky MS. Endothelin and nitric oxide in hepatorenal syndrome: a balance reset. J Nephrol 1997;10:120-35.
46. Lang F, Tschernko E, Schulze E, et al. Hepatorenal reflex regulating kidney function. Hepatology 1991;14:590-4.
47. Jalan R, Forrest EH, Redhead DN, Dillon JH, Hayes PC. Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man? Gut 1997;50:664-70.
48. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995;22:332-54.